Skip to main content

Table 3 Survival data stratified according to relapse location and treatment modality; n = 87

From: Site of relapse of ductal adenocarcinoma of the pancreas affects survival after multimodal therapy

  DFS before 2nd treatment A DFS before surgery A RSS after surgery
B DFS before chemotherapy B RSS after chemotherapy
Median (months) 95%CI   Median (months) 95%CI   Median (months) 95%CI
Pulmonary 18.15 0.30–35.99 A 22.85 14.10–31.64 A 61.71
B 7.63 4.76–10.49 B 5.99 0.0–12.3
  p-value 0.012 p-value 0.005
Hepatic 7.83 5.76–9.89 A 7.47 0.00–15.56 A 8.39 1.52–15.26
B 7.83 5.75–9.90 B 4.84 1.25–8.42
    p-value 0.897 p-value 0.829
Local 10.55 7.14–13.96 A 10.75 2.30–19.22 A 51.85 24.65–79.10
B 7.95 2.10–13.84 B 6.20 3.41–9.89
    p-value 0.972 p-value 0.006
  1. Patients with isolated pulmonary metastases showed the best DFS. Surgery significantly influenced PRS in patients with isolated pulmonary metastases and local recurrence. Log rank test was used to test for statistical significance. p-value ≤ 0.05 indicates significance
  2. CI confidence interval, DFS disease free survival, RSS relapse specific survival, 2nd treatment relapse surgery or relapse chemotherapy